Dr Reddy's Laboratories' Indian drug maker received a warning letter from the US Food and Drug Administration (FDA) to its Mexican facility for violating manufacturing standards. FDA has imposed an import ban on products made at this unit of the company. FDA warned the company that failure to correct these violations may see the regulator refuse entry into the United States, a key export market for the firm, of products manufactured at Dr Reddy's Mexican facility.
Recently Dr Reddy’s Laboratories has launched Levofloxacin tablets 250mg, 500mg, and 750mg, a bioequivalent generic version of Levaquin tablets in the US market on June 20, 2011, following the approval by the United States Food and Drug Administration (USFDA) of the company’s Abbreviated New Drug Application (ANDA) for Levofloxacin tablets.
The company’s net profit for the fourth quarter declined by 34.48% at Rs 165.87 crore as compared to Rs 253.16 crore for the corresponding quarter previous year. Its total income increased by 7.11% at Rs 1375.77 crore for the quarter under review from Rs 1284.43 crore in the corresponding previous quarter.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1863.45 |
| Dr. Reddys Lab | 1291.05 |
| Cipla | 1415.30 |
| Zydus Lifesciences | 1084.35 |
| Lupin | 2339.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: